Nouscom AG
Biotechnology ResearchBasel-stadt, Switzerland51-200 Employees
Nouscom is a clinical-stage biotech company redefining cancer immunotherapy through its proprietary viral vector platform. Headquartered in Basel, Switzerland, Nouscom develops both off-the-shelf and personalized neoantigen immunotherapies that activate robust and durable T cell responses in cancer patients. Our lead program, NOUS-209, is advancing toward registrational for cancer interception in Lynch Syndrome carriers, a transformative opportunity for these patients. The program has received positive regulatory feedback with a global registrational trial expected to launch in H1 2026. Nouscom’s second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. It has demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process that enables scalable delivery within 8 weeks. Nouscom is supported by leading life sciences investors including 5AM Ventures, Andera Partners, M Ventures, Bpifrance, EQT Life Sciences, Indacos, Panakes, Revelation, Versant Ventures and XGen Ventures. Our platform is clinically validated in over 170 patients and offers unmatched immunogenicity, scalability, and safety — positioning Nouscom as a frontrunner in the next generation of cancer immunotherapy. 🔗 Learn more at http://www.nouscom.com
1-888-653-2347 
support@leadiq.com 
